17 29

Cited 0 times in

Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study

DC FieldValueLanguage
dc.contributor.author조병철-
dc.date.accessioned2020-12-01T16:55:27Z-
dc.date.available2020-12-01T16:55:27Z-
dc.date.issued2020-09-
dc.identifier.issn0169-5002-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/180047-
dc.description.abstractIntroduction: In the phase II ATLANTIC study, durvalumab provided durable responses with acceptable tolerability in heavily pretreated patients with advanced NSCLC, across three independent patient cohorts defined by EGFR/ALK status and tumour PD-L1 expression. Preliminary overall survival (OS) data were encouraging. We now report final OS and updated safety data. Methods: Patients with advanced NSCLC with disease progression following ≥2 previous systemic regimens received durvalumab 10 mg/kg every 2 weeks. The primary endpoint was objective response rate among patients with increased PD-L1 expression (defined as ≥25 % or ≥90 % of tumour cells [TCs], cohort-dependent). Secondary endpoints included OS and safety. Results: 444 patients received durvalumab: 111 in Cohort 1 (EGFR+/ALK+), 265 in Cohort 2 (EGFR-/ALK-), and 68 in Cohort 3 (EGFR-/ALK-; TC ≥ 90 %). Median (95 % CI) OS was 13.3 months (6.3-24.5) in patients with EGFR+/ALK+ NSCLC with TC ≥ 25 %, 10.9 months (8.6-13.6) in patients with EGFR-/ALK- NSCLC with TC ≥ 25 %, and 13.2 months (5.9-not reached) in patients with EGFR-/ALK- NSCLC with TC ≥ 90 %. Median (95 % CI) OS was slightly shorter in patients with TC < 25 % (9.9 months [4.2-13.3] in patients with EGFR+/ALK+ NSCLC and 9.3 months [5.9-10.8] in those with EGFR-/ALK- NSCLC). Treatment-related adverse events of special interest occurred with similar incidences as reported previously. Conclusions: After additional follow-up, final OS data remain encouraging across all cohorts, further supporting the clinical activity of durvalumab in patients with heavily pretreated advanced NSCLC, including those with EGFR+/ALK+ tumours. There were no new safety signals. Trial registration: ClinicalTrials.gov NCT02087423.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherElsevier Scientific Publishers-
dc.relation.isPartOfLUNG CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleFinal overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorMarina Chiara Garassino-
dc.contributor.googleauthorByoung-Chul Cho-
dc.contributor.googleauthorJoo-Hang Kim-
dc.contributor.googleauthorJulien Mazières-
dc.contributor.googleauthorJohan Vansteenkiste-
dc.contributor.googleauthorHervé Lena-
dc.contributor.googleauthorJesus Corral Jaime-
dc.contributor.googleauthorJhanelle E Gray-
dc.contributor.googleauthorJohn Powderly-
dc.contributor.googleauthorChristos Chouaid-
dc.contributor.googleauthorPaolo Bidoli-
dc.contributor.googleauthorPaul Wheatley-Price-
dc.contributor.googleauthorKeunchil Park-
dc.contributor.googleauthorRoss A Soo-
dc.contributor.googleauthorLynne Poole-
dc.contributor.googleauthorCatherine Wadsworth-
dc.contributor.googleauthorPhillip A Dennis-
dc.contributor.googleauthorNaiyer A Rizvi-
dc.identifier.doi10.1016/j.lungcan.2020.06.032-
dc.contributor.localIdA03822-
dc.relation.journalcodeJ02174-
dc.identifier.eissn1872-8332-
dc.identifier.pmid32702570-
dc.subject.keywordATLANTIC-
dc.subject.keywordDurvalumab-
dc.subject.keywordNSCLC-
dc.subject.keywordOverall survival-
dc.subject.keywordSafety-
dc.contributor.alternativeNameCho, Byoung Chul-
dc.contributor.affiliatedAuthor조병철-
dc.citation.volume147-
dc.citation.startPage137-
dc.citation.endPage142-
dc.identifier.bibliographicCitationLUNG CANCER, Vol.147 : 137-142, 2020-09-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.